MediWound Says NexoBrid US Launch Expected In Early Q3 Of 2023
Portfolio Pulse from Benzinga Newsdesk
MediWound announced the expected US launch of NexoBrid in early Q3 of 2023 and plans to expand its manufacturing facility to meet increasing global demand. The expansion project is set to be completed by the end of 2024, increasing production capacity by five-fold. The company's global Phase III clinical study for EscharEx is expected to begin in Q4 of 2023.
May 30, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediWound's announcement of NexoBrid's US launch in Q3 2023, manufacturing facility expansion, and EscharEx Phase III clinical study may positively impact its stock price.
The announcement of NexoBrid's US launch, expansion of the manufacturing facility, and the upcoming Phase III clinical study for EscharEx indicate potential growth for MediWound. These developments may attract investors and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100